

**Aurelio Caruso**

**Casa di cura San Michele**

**Maddaloni – (Caserta)**



**L'insufficienza tricuspидale: una valvulopatia spesso trascurata. Come dare al cardiocirurgo tutte le informazioni per decidere l'indicazione operatoria**

EcoCardioChirurgia è un marchio che abbiamo registrato molti anni fa per esprimere con una sola parola lo spirito ed i promotori dell'iniziativa.

Abbiamo, infatti, iniziato la nostra attività a Milano nel 2004 coinvolgendo, sia dal primo incontro a carattere locale del 20-21 maggio 2004, cardiologi, cardiocirurghi, cardiocirurghi, cardiocirurghi, medici di medicina d'urgenza, internisti, radiologi che si sono sempre confrontati in uno spazio nel quale gli interessi delle singole specialità sono stati subordinati alla continua ricerca del miglior percorso diagnostico / terapeutico del paziente.

Da sempre ci ha sempre guidato il desiderio di incontrarci per migliorare la qualità del nostro lavoro orientandoci al continuo aggiornamento degli specialisti che si occupano del cardiopatico più delicato: quello destinato alla cardiocirurgia o alle tecniche interventistiche.

Grande è la nostra soddisfazione per aver pensato ad un lavoro in "Heart Team" quando ancora nessuno ne parlava.

Questo particolare tipo d'impostazione ha riscosso l'interesse dei nostri colleghi ed ora siamo quindi giunti alla VII edizione del Congresso Nazionale, ma che per noi tutti è il "Congresso del X anno di EcoCardioChirurgia".

La formula è quella ormai consueta che ha per obiettivi la formazione continua dei partecipanti e per metodo divulgativo la suddivisione degli argomenti tra quelli di largo target e quelli di nicchia: i primi vengono trattati in auditorium in sedute plenarie ed i secondi in salette a forte interazione discendente/docente. Teniamo particolarmente a chiarire che per noi "nicchia" non vuole dire "poco importante". E per testimoniarlo abbiamo sempre coinvolto i maggiori esperti su scala nazionale anche per trattare gli argomenti più particolari.

Vi diamo il benvenuto a Milano, pronti ad un'attiva partecipazione e Vi invitiamo sin d'ora ad iscriverVi alla nostra comunità scientifica come "fellow" di EcoCardioChirurgia registrandoVi nel sito: [www.ecocardiochirurgia.it](http://www.ecocardiochirurgia.it)




*Luciano Affareno*




*Giuseppe Tanelli*

VII CONGRESSO DI **ECOCARDIOCHIRURGIA**







# La tricuspide...questa cenerentola



# PER L'ECOCARDIOGRAFISTA.....

Lossy compression - not intended for diagnosis





# PER IL CARDIOCHIRURGO.....

- ✘ Aumento del rischio operatorio ?
- ✘ Riparazione spesso deludente
- ✘ Sostituzione problematica
- ✘ Criteri di indicazione non sempre condivisi

.....ma non per intervento contemporaneo  
a chirurgia sul cuore sinistro

**Recidiva a 5 anni:**

**20-35% per De Vega**


**10% per anello protesico**

**Table 16** Indications for tricuspid valve surgery

	Class <sup>a</sup>	Level <sup>b</sup>
Surgery is indicated in symptomatic patients with severe TS. <sup>c</sup>	I	C
Surgery is indicated in patients with severe TS undergoing left-sided valve intervention. <sup>d</sup>	I	C
Surgery is indicated in patients with severe primary or secondary TR undergoing left-sided valve surgery.	I	C
Surgery is indicated in symptomatic patients with severe isolated primary TR without severe right ventricular dysfunction.	I	C
Surgery should be considered in patients with moderate primary TR undergoing left-sided valve surgery.	IIa	C
Surgery should be considered in patients with mild or moderate secondary TR with dilated annulus ( $\geq 40$ mm or $>21$ mm/m <sup>2</sup> ) undergoing left-sided valve surgery.	IIa	C
Surgery should be considered in asymptomatic or mildly symptomatic patients with severe isolated primary TR and progressive right ventricular dilatation or deterioration of right ventricular function.	IIa	C
After left-sided valve surgery, surgery should be considered in patients with severe TR who are symptomatic or have progressive right ventricular dilatation/dysfunction, <i>in the absence</i> of left-sided valve dysfunction, severe right or left ventricular dysfunction, and severe pulmonary vascular disease.	IIa	C

**Table 2** Levels of evidence


Level of evidence A	Data derived from multiple randomized clinical trials or meta-analyses.
Level of evidence B	Data derived from a single randomized clinical trial or large non-randomized studies.
Level of evidence C	Consensus of opinion of the experts and/or small studies, retrospective studies, registries.



**Figure 1.** Kaplan-Meier survival curves for all patients with tricuspid regurgitation (TR). Survival is significantly worse in patients with moderate and severe TR.

*Shiran and Sagie,  
JACC 2009;53:401-8*

*Nath et al. JACC 2004;43:405-9*




**Figure 2**

**Event-Free Survival After Balloon Mitral Valvotomy by TR Severity**





# studiare la tricuspide da diversi “punti di vista”

4camere  
apicale









parasternale  
long-axis  
afflusso dx

10:16:42




parasternale short-axis



10:18:21



sottocostale



10:18:59



sottocostale  
short-axis



10:18:59



CTO




e si scopre che.....

4camere  
apicale




parasternale  
long-axis  
afflusso dx








4camere  
apicale

77  
LD



parasternale  
long-axis  
afflusso dx







.....fino ad ora senza color!



12:32:50



# Insufficienza tricuspide



# INSUFFICIENZA TRICUSPIDALE

## Primitiva (più rara)

- ✗ Reumatica
- ✗ Endocardite
- ✗ Prolasso
- ✗ Carcinoide
- ✗ Ebstein
- ✗ Rottura traumatica


## Secondaria (più frequente) (dilatazione anulare e tethering dei lembi)

- ✗ Sovraccarico di pressione
  - + Patologia cuore sx
  - + Cuore polmonare
  - + Ipertensione polm. primitiva
- ✗ Sovraccarico volume VDx:
  - + Difetto interatriale
  - + Disfunzione ventricolare dx

✗ pace maker

✗ fibrillazione atriale

✗ età avanzata



Come valutarla?








## European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease)


Patrizio Lancellotti (Chair)<sup>1\*</sup>, Luis Moura<sup>2</sup>, Luc A. Pierard<sup>1</sup>, Eustachio Agricola<sup>3</sup>, Bogdan A. Popescu<sup>4</sup>, Christophe Tribouilloy<sup>5</sup>, Andreas Hagendorff<sup>6</sup>, Jean-Luc Monin<sup>7</sup>, Luigi Badano<sup>8</sup>, and Jose L. Zamorano<sup>9</sup> on behalf of the European Association of Echocardiography

**The colour flow area of the regurgitant jet is not recommended to quantify the severity of TR. The colour flow imaging should only be used for diagnosing TR. A more quantitative approach is required when more than a small central TR jet is observed.**










Vena contracta  
 $\geq 7$  mm: IT severa  
 $< 6$  mm: IT moderata o lieve



APICAL 4-CV

V

A

B

PISA

E

PISA

ERO  $\geq 40$  mm<sup>2</sup>  
Vol R  $\geq 45$  ml  
x IT severa

radius




10

TR ERO 0.4 cm<sup>2</sup>

EROA 40 mm<sup>2</sup>

R Vol 49 ml

TVI






raggio PISA (a 28 cm/s Nyquist)

> 9 mm

< 5 mm

IT severa

IT lieve






2	Vmax	1.53 m/s
	Vmedia	0.78 m/s
	Pmax	9.37 mmHg
	Pmean	2.97 mmHg
	Env.Ti	394 ms
	VTI	30.5 cm
	HR	152 BPM
1	Vmax	2.64 m/s
	Vmedia	2.02 m/s
	Pmax	27.94 mmHg
	Pmean	17.77 mmHg
	Env.Ti	299 ms
	VTI	60.4 cm
	HR	200 BPM







Onda E  $\geq 1$  m/s:  
IT severa

27	v	0.93 m/s
	p	3.44 mmHg
	v	0.92 m/s
	p	3.40 mmHg
	Frq	2.36 kHz




ESC 2010




The systolic hepatic flow reversal is specific for severe TR. It represents **the strongest** additional parameter for evaluating the severity of TR.

# CONTRO I TRANELLI DEL COLOR.....



4 camere






parasternale  
afflusso dx

...IL SOCCORSO DI CLINICA

→ epatomegalia  
pulsante

... E VALUTAZIONE POLIPARAMETRICA







Coaptation Distance  
> 8 mm  
Tenting area  
> 1cm<sup>2</sup>


3	L	1.2 cm
2	A	2.3 cm <sup>2</sup>

5:31:47

CTO









- Anulus tricuspидale : v.n. 28 mm  $\pm$  5
- La sua area si riduce in sistole del 25%
- Dilatazione significativa: > 35 mm o 21 mm/m<sup>2</sup>BSA

## Surgical view



$\geq 4$  cm or 21 mm/m<sup>2</sup>



septal to anterior leaflet distance



**Table 16** Indications for tricuspid valve surgery

	Class <sup>a</sup>	Level <sup>b</sup>
Surgery is indicated in symptomatic patients with severe TS. <sup>c</sup>	I	C
Surgery is indicated in patients with severe TS undergoing left-sided valve intervention. <sup>d</sup>	I	C
Surgery is indicated in patients with severe primary or secondary TR undergoing left-sided valve surgery.	I	C
Surgery is indicated in symptomatic patients		

Surgery should be considered in patients with mild or moderate secondary TR with dilated annulus ( $\geq 40$  mm or  $> 21$  mm/m<sup>2</sup>) undergoing left-sided valve surgery.

**IIa**

**C**

Surgery should be considered in asymptomatic or mildly symptomatic patients with severe isolated primary TR and progressive right ventricular dilatation or deterioration of right ventricular function.	IIa	C
After left-sided valve surgery, surgery should be considered in patients with severe TR who are symptomatic or have progressive right ventricular dilatation/dysfunction, <i>in the absence</i> of left-sided valve dysfunction, severe right or left ventricular dysfunction, and severe pulmonary vascular disease.	IIa	C

**Table 5 Grading the severity of TR**

Parameters	Mild	Moderate	Severe
Qualitative			
Tricuspid valve morphology	Normal/abnormal	Normal/abnormal	Abnormal/flail/large coaptation defect
Colour flow TR jet <sup>a</sup>	Small, central	Intermediate	Very large central jet or eccentric wall impinging jet
CW signal of TR jet	Faint/Parabolic	Dense/Parabolic	Dense/Triangular with early peaking (peak <2 m/s in massive TR)
Semi-quantitative			
VC width (mm) <sup>a</sup>	Not defined	<7	≥7
PISA radius (mm) <sup>b</sup>	≤5	6–9	>9
Hepatic vein flow <sup>c</sup>	Systolic dominance	Systolic blunting	Systolic flow reversal
Tricuspid inflow	Normal	Normal	E wave dominant (≥1 cm/s) <sup>d</sup>
Quantitative			
EROA (mm <sup>2</sup> )	Not defined	Not defined	≥40
R Vol (mL)	Not defined	Not defined	≥45
+ RA/RV/IVC dimension <sup>e</sup>			

**Table 6** Echocardiographic parameters used to quantify tricuspid regurgitation severity: recordings, advantages, and limitations

**Table 6** Echocardiographic parameters used to quantify tricuspid regurgitation severity: recordings, advantages, and limitations

Parameters	Recordings	Usefulness/advantages	Limitations
Tricuspid valve morphology	<ul style="list-style-type: none"> <li>• Visual assessment</li> <li>• Multiple views</li> </ul>	<ul style="list-style-type: none"> <li>• Flail valve is specific for significant TR</li> </ul>	<ul style="list-style-type: none"> <li>• Other abnormalities are non-specific of significant TR</li> </ul>
Tricuspid annulus diameter	<ul style="list-style-type: none"> <li>• Apical four-chamber view</li> <li>• Lateral inner edge to septal inner edge</li> </ul>	<ul style="list-style-type: none"> <li>• Dilatation sensitive for severe TR</li> </ul>	<ul style="list-style-type: none"> <li>• Dilatation seen in other conditions</li> <li>• Need to be confirmed in further studies</li> </ul>
Colour flow TR jet	<ul style="list-style-type: none"> <li>• Optimize colour gain/scale</li> <li>• Evaluate in two views</li> <li>• Need blood pressure evaluation</li> </ul>	<ul style="list-style-type: none"> <li>• Ease of use</li> <li>• Evaluates the spatial orientation of TR jet</li> <li>• Good screening test for mild vs. severe TR</li> </ul>	<ul style="list-style-type: none"> <li>• Can be inaccurate for estimation of TR severity</li> <li>• Influenced by technical and haemodynamic factors</li> <li>• Underestimates eccentric jet adhering the RA wall (Coanda effect)</li> </ul>



<ul style="list-style-type: none"> <li>• Decrease the Nyquist limit (colour flow zero baseline)</li> <li>• With the cine mode select the best PISA</li> <li>• Display the colour off and on to visualize the TR orifice</li> <li>• Measure the PISA radius at mid-systole using the first aliasing and along the direction of the ultrasound beam</li> <li>• Measure TR peak velocity and TVI (CW)</li> <li>• Calculate flow rate, EROA, R Vol</li> </ul>	<ul style="list-style-type: none"> <li>• Quantitative: estimate lesion severity (EROA) and volume overload (R Vol)</li> <li>• Large flow convergence at 28 cm/s alerts to significant TR</li> </ul>	<ul style="list-style-type: none"> <li>• Errors in PISA radius measurement are squared</li> <li>• Inter-observer variability</li> <li>• Validated in only few studies</li> </ul>
<ul style="list-style-type: none"> <li>• Apical four-chamber</li> </ul>	<ul style="list-style-type: none"> <li>• Simple, easily available</li> </ul>	<ul style="list-style-type: none"> <li>• Qualitative, Complementary finding</li> <li>• Complete signal difficult to obtain in eccentric jet</li> </ul>
<ul style="list-style-type: none"> <li>• Subcostal view</li> <li>• Sample volume of PW places into the hepatic vein</li> </ul>	<ul style="list-style-type: none"> <li>• Simple</li> <li>• Systolic flow reversal is specific for severe TR</li> </ul>	<ul style="list-style-type: none"> <li>• Affected by RA pressure, atrial fibrillation</li> </ul>
<ul style="list-style-type: none"> <li>• Apical four-chamber</li> <li>• Sample volume of PW places at tricuspid leaflet tips</li> </ul>	<ul style="list-style-type: none"> <li>• Simple, easily available</li> <li>• Usually increased in severe TR</li> </ul>	<ul style="list-style-type: none"> <li>• Affected by RA pressure, atrial fibrillation, RV relaxation</li> <li>• Complementary finding</li> </ul>

Continued







F  
67 anni  
Valvulopatia reumatica



Lossy compression - not intended for diagnosis



Sostituzione mitralica  
con S.Jude 29 mm





Lossy compression - not intended for diagnosis





- M
- 68 anni
- Commissurotomia M + Sorin 23 Ao 24 anni fa
- IT moderata 10 anni fa
- scompenso congestizio da alcuni mesi
- ascite

Lossy compression - not intended for diagnosis







## Reintervento:

- Anello TR Edwards MC3 n.30
- Protesi mitralica s. Jude 29
- Asintomatico








- F
- 74 anni
- Fibrillazione atriale cronica
- Scompenso con ascite e versamento pleurico bilaterale




Pressione polmonare  
26 mmHg






**Controls**



**IT "idiopatica"  
associata a f.a.  
ed età avanzata**



**IT da Ipertensione  
polmonare**




Lossy compression - not intended for diagnosis



F  
82 anni  
PM endocavitario  
Ripetuti episodi di scompenso

Lossy compression - not intended for diagnosis




Lossy compression - not intended for diagnosis




Interferenza del catetere stimolatore???

- F
- 69 anni
- PM endocavitario da un anno
- ECG: RS- BAV I° grado
- Stenosi Ao e M serrate






Lossy compression - not intended for diagnosis




Lossy compression - not intended for diagnosis



....dopo un anno da  
impianto di bioprotesi Ao e M  
Epatomegalia pulsante  
ECG: fibrillazione atriale

PAP sist.36 mmHg  
media 15 mmHg




Lossy compression - not intended for diagnosis




Interferenza del catetere stimolatore???

Fibrillazione atriale?

25-29% dei pz con PM o ICD




(F) asynchrony








- M
- 65 anni
- Iperteso
- Resezione intestinale per neoplasia imprecisata 20 anni prima
- anoressizzanti per 2 mesi a 15 anni di età
- recente scompenso congestizio



2 A	31.1 cm <sup>2</sup>
1 Ls	5.6 cm
As	18.3 cm <sup>2</sup>
ESV(A-L)	51 ml
ESV(MOD)	48 ml







Acido 5 idrossiindolacetico  
nelle urine indosabile per  
eccesso di quantità



**CARCINOIDE**



# CONCLUSIONI

## VALUTAZIONE ECOCARDIOGRAFICA DELLA TRICUSPIDE:

---

### Omnicomprensiva e poliparametrica

- ✘ Lembi
- ✘ Anulus
- ✘ Cavità dx
- ✘ VCI e sovraepatiche
- ✘ Dati color e doppler multipli e integrati

